Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài:Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS. | Int. J. Med. Sci. 2011 8 332 o IVYSPRING . PUBLSHEK International Journal of Medical Sciences 2011 8 4 332-338 Research Paper Platinum Agent-Induced Hypersensitivity Reactions Data Mining of the Public Version of the FDA Adverse Event Reporting System AERS Toshiyuki Sakaeda 1X Kaori Kadoyama 1 Hiroaki Yabuuchi 2 3 Satoshi Niijima 2 Kyoko Seki 4 Yukinari Shiraishi 4 and Yasushi Okuno 2 3X 1. Center for Development of Integrative Education in Pharmacy and Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan 2. Department of Systems Biosciences for Drug Discovery Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan 3. Kyoto Constella Technologies Co. Ltd. Kyoto 604-8156 Japan 4. Department of Pharmacy Japan Labour Health and Welfare Organization Kobe Rosai Hospital Kobe 651-0053 Japan H Corresponding author Toshiyuki Sakaeda . Center for Development of Integrative Education in Pharmacy and Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan Tel 81-75-753-9560 Fax 81-75-753-4502 e-mail sakaedat@ Yasushi Okuno . Department of Systems Biosciences for Drug Discovery Graduate School of Pharmaceutical Sciences Kyoto University Kyoto 606-8501 Japan Tel Fax 81-75-753-4559 e-mail okuno@ Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License http licenses by-nc-nd . Reproduction is permitted for personal noncommercial use provided that the article is in whole unmodified and properly cited. Received Accepted Published Abstract Objective Adverse event reports AERs submitted to the US Food and Drug Administration FDA were reviewed to confirm the platinum agent-associated mild severe and lethal hypersensitivity reactions. Methods Authorized pharmacovigilance tools were .
